Trial Profile
A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson's disease who suffer motor fluctuations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics; Proof of concept
- Sponsors SynAgile Corporation
- 19 Oct 2015 New trial record